Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky(Tisch Hospital), Jóse Ángel Arranz Arija(Hospital General Universitario Gregorio Marañón), Aristotelis Bamias(National and Kapodistrian University of Athens), Ian D. Davis(Eastern Health), Maria De Santis(Medical University of Vienna), Eiji Kikuchi(Keio University), Xavier García del Muro(Institut d'Investigació Biomédica de Bellvitge), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marina Mencinger(Institute of Oncology Ljubljana), Kouji Izumi(Kanazawa University Hospital), Stefano Panni(Istituti Ospitalieri di Cremona), Mahmut Gümüş(Istanbul Medeniyet University), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Arash Rezazadeh Kalebasty(Norton Healthcare), Se Hoon Park(Samsung Medical Center), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Fabio A. Schutz(Beneficência Portuguesa de São Paulo), Jian-Ri Li(Taichung Veterans General Hospital), Dingwei Ye(Fudan University Shanghai Cancer Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Sandrine Bernhard(Roche (United Kingdom)), Darren Tayama, Sanjeev Mariathasan, Almut Mecke(Roche (Switzerland)), AnnChristine Thåström, Enrique Grande(MD Anderson Cancer Center Madrid)
Cited by 782Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis